BioCorRx IncOTCQB:BICX
- LAST PRICE1.4700
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close1.4800 / 1.4700
- Day Range
- 52 Week Range
- Volume2,656
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BICX |
|---|---|---|
| 01:10 ET | 360 | 1.05 |
| 03:52 ET | 2100 | 1.47 |
Apr 3, 2024
BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia, from 8:30AM ET on Wednesday Apr 03, 2024 by Dow Jones
8:30AM ET on Wednesday Apr 03, 2024 by Dow Jones
Apr 2, 2024
BioCorRx Reports Business Update for 2023, from 8:30AM ET on Tuesday Apr 02, 2024 by Dow Jones
8:30AM ET on Tuesday Apr 02, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
BioCorRx Inc | 13.0M | -3.2x | --- |
Univec Inc | 12.6M | 0.0x | --- |
PharmChem Inc | 12.6M | 18.6x | --- |
US Neurosurgical Holdings Inc | 10.0M | -7.8x | --- |
Healthlynked Corp | 14.3M | -3.7x | --- |
Medical Care Technologies Inc | 16.4M | 0.0x | --- |
Company Information
BioCorRx Inc., through its subsidiaries, develops and provides addiction treatment solutions for the treatment of substance use and other related disorders. Its Beat Addiction Recovery is a substance use disorder recovery program that typically includes its Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app along with medication prescribed by an independent treating physician under their discretion. The UnCraveRx Weight Loss Program is also a medication-assisted weight loss program that includes access to concierge on-demand wellness specialists, nutritionists, fitness experts, and personal support from behavioral experts. The Company, through its subsidiary, BioCorRx Pharmaceuticals Inc., is engaged in the development of BICX104, a subcutaneous implantable naltrexone pellet for the treatment of both opioid and alcohol use disorders. It is also engaged in the establishment of alcoholism and opioid addiction rehabilitation and treatment centers.
Contact Information
- Headquarters
- 2390 East Orangewood Avenue, Suite 500ANAHEIM, CA, United States 92806
- Phone
- 714-462-4880
- Fax
- ---
Executives
- President, Director
- Louis Lucido
- Chief Executive Officer, Chief Financial Officer, Director
- Lourdes Felix
- Executive Vice President
- Thomas Welch
- Independent Director
- Kent Emry
- Independent Director
- Joseph Galligan
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $13.0M |
|---|---|
Revenue (TTM) | $89.2K |
Shares Outstanding | 8.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.33 |
EPS | $-0.45 |
Book Value | $-1.13 |
P/E Ratio | -3.2x |
Price/Sales (TTM) | 145.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -4,286.33% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
